Literature DB >> 30952393

Mobile Apps for Rheumatoid Arthritis: Opportunities and Challenges.

Elizabeth Mollard1, Kaleb Michaud2.   

Abstract

Mobile applications have the potential to improve health outcomes in patients with rheumatoid arthritis (RA). Whereas other chronic diseases such as diabetes and heart failure have a well-established presence in the mobile application realm, apps focused on RA are still in their infancy. This article presents an overview of the types of mobile apps that can be used for RA and discusses the opportunities and challenges associated with them.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mhealth; Mobile applications; Rheumatoid arthritis; Self-management; Smartphone

Mesh：

Year:  2019        PMID： 30952393     DOI： 10.1016/j.rdc.2019.01.011

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  9 in total

Review 1.  "Mobile Health" for the Management of Spondyloarthritis and Its Application in China.

Authors:  Xiaojian Ji; Lidong Hu; Yiwen Wang; Yiming Luo; Jian Zhu; Jianglin Zhang; M A Khan; Feng Huang
Journal:  Curr Rheumatol Rep       Date:  2019-11-19       Impact factor: 4.592

2.  Plumbagin relieves rheumatoid arthritis through nuclear factor kappa-B (NF-κB) pathway.

Authors:  Chang Shu; Jun Chen; Meiyan Lv; Yiyuan Xi; Jujia Zheng; Xiangwei Xu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits.

Authors:  Bryant R England; Claire E H Barber; Martin Bergman; Veena K Ranganath; Lisa G Suter; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-12       Impact factor: 5.178

4.  Patient Perspectives on a Digital Mobile Health Application for RA.

Authors:  Simran Chahal; Norma Biln; Bruce Clarke
Journal:  Open Access Rheumatol       Date:  2021-04-23

5.  Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction.

Authors:  Yomei Shaw; Delphine S Courvoisier; Almut Scherer; Adrian Ciurea; Thomas Lehmann; Veronika K Jaeger; Ulrich A Walker; Axel Finckh
Journal:  RMD Open       Date:  2021-04

6.  The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search.

Authors:  Rosa Romero-Jimenez; Vicente Escudero-Vilaplana; Esther Chamorro-De-Vega; Arantza Ais-Larisgoitia; Maria Elena Lobato Matilla; Ana Herranz-Alonso; Maria Sanjurjo
Journal:  J Med Internet Res       Date:  2022-03-04       Impact factor: 7.076

7.  Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare.

Authors:  Rosa Romero-Jimenez; Vicente Escudero-Vilaplana; Esther Chamorro-de-Vega; Arantza Ais-Larisgoitia; Elena Lobato-Matilla; Beatriz Somoza-Fernández; Paula Ruiz-Briones; Carlos González; Ofelia Baniandrés; Luis Menchén; Carmen Lobo-Rodríguez; Ana Herranz; María Sanjurjo
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

8.  Development and real-life use assessment of a self-management smartphone application for patients with inflammatory arthritis. A user-centred step-by-step approach.

Authors:  Catherine Beauvais; Thao Pham; Guillaume Montagu; Sophie Gleizes; Francesco Madrisotti; Alexandre Lafourcade; Céline Vidal; Guillaume Dervin; Pauline Baudard; Sandra Desouches; Florence Tubach; Julian Le Calvez; Marie de Quatrebarbes; Delphine Lafarge; Laurent Grange; Françoise Alliot-Launois; Henri Jeantet; Marie Antignac; Sonia Tropé; Ludovic Besset; Jérémie Sellam
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

9.  Telemedicine in rheumatology: a reliable approach beyond the pandemic.

Authors:  Lorenzo Cavagna; Giovanni Zanframundo; Veronica Codullo; Maria Grazia Pisu; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.